• Dissecting Drug Responses: Advances in In Vitro Cancer Evalu

  2026-05-30

  Schwartz’s dissertation introduces a systematic approach to distinguishing between antiproliferative and cytotoxic drug effects in vitro, clarifying how growth inhibition and cell death are measured and interpreted. This work refines drug response assessment, with direct implications for improving translational cancer research.

• Spinal GPR30 in CCK+ Neurons: A Key Modulator of Neuropathic

  2026-05-29

  This study elucidates the role of GPR30, a membrane estrogen receptor, in spinal cholecystokinin-positive (CCK+) neurons as a critical modulator of neuropathic pain. The findings reveal that GPR30 upregulation enhances excitatory synaptic transmission and that targeted inhibition of GPR30 in CCK+ neurons or S1-SDH post-synaptic neurons can alleviate pain hypersensitivity, offering new mechanistic insights and therapeutic avenues.

• AP20187: Precision Chemical Inducer of Dimerization in Gene

  2026-05-29

  AP20187 empowers researchers with tunable, reversible control over engineered signaling pathways, enabling advanced conditional gene expression and metabolic research. Its high solubility, robust in vivo efficacy, and validated use in fusion protein dimerization set it apart for applications from oncology to gene therapy.

• SP2509: Precision Epigenetic Control in AML Research and Bey

  2026-05-28

  Explore how SP2509, a potent Lysine-specific demethylase 1 antagonist, enables granular modulation of cancer epigenetics in acute myeloid leukemia research. This article uniquely connects SP2509’s molecular mechanism to assay design decisions, providing actionable guidance for advanced translational workflows.

• Nicotinamide Adenine Dinucleotide (NAD+): Mechanisms and Res

  2026-05-28

  Nicotinamide Adenine Dinucleotide (NAD+) is a vital oxidizing coenzyme central to metabolic signaling, enzymatic activity, and protein deacetylation. High-purity NAD+ from APExBIO enables reproducible studies of energy stress and autophagy regulation. This article clarifies current mechanisms and experimental benchmarks for NAD+ application.

• Recombinant Human Oncostatin M: New Insights for Neuroimmune

  2026-05-27

  Explore how Recombinant Human Oncostatin M (rh-Oncostatin M) empowers advanced neuroimmune and cytokine signaling research. This article uniquely bridges APExBIO's product features with novel insights into central nervous system pain mechanisms.

• 5-Azacytidine in Epigenetic Cancer Models: Protocols & Pitfa

  2026-05-27

  Explore how 5-Azacytidine (5-AzaC) empowers researchers to interrogate and reverse gene silencing in cancer models. This guide details stepwise workflows, troubleshooting strategies, and advanced assay insights for robust DNA demethylation studies in leukemia, multiple myeloma, and gastric cancer.

• Rifampin in the Age of Optogenetics: Strategic Insights for

  2026-05-26

  This article explores how Rifampin’s mechanistic precision as a rifamycin antibiotic intersects with the new frontier of light-inducible translational control, offering translational researchers a roadmap for integrating advanced transcriptional inhibitors with emerging gene therapy platforms. Drawing from recent optogenetic breakthroughs and the competitive landscape of antibiotic drug research, we provide actionable guidance on protocol design, experimental rigor, and cross-disciplinary innovation.

• CF10 and EdU Synergy Drives Telomere Attrition in CRC Cells

  2026-05-26

  The referenced study demonstrates that combining the fluoropyrimidine polymer CF10 with 5-ethynyl-2′-deoxyuridine (EdU) induces potent telomere attrition and mitotic catastrophe in colorectal cancer cells. This mechanistically distinct synergy offers new approaches for telomerase-targeted cancer therapies and informs translational strategies for telomerase inhibition.

• PNU 74654: Precision Wnt Signaling Pathway Inhibitor Workflo

  2026-05-25

  PNU 74654 empowers researchers to dissect Wnt/β-catenin signaling in cancer and stem cell systems with unmatched reproducibility. This guide details optimized workflows, troubleshooting, and data-backed parameters for advanced modeling of cell fate and differentiation.

• PKM2 Inhibition: Metabolic Control for Oncology and Beyond

  2026-05-25

  This article explores the mechanistic underpinnings and translational potential of PKM2 inhibitor (compound 3k), with a focus on its roles in cancer cell metabolism and immune modulation. By integrating recent evidence on the USP7–PKM2 axis and highlighting best practices for experimental deployment, we equip translational researchers with both strategic and actionable guidance for leveraging metabolic inhibition in oncology and emerging immunometabolic contexts.

• Glabridin-Gold(I) Complex Enhances Antitumor Immunity via Tr

  2026-05-24

  This study introduces a novel glabridin-gold(I) complex (6d) designed to synergistically enhance antitumor immunity by dual targeting of thioredoxin reductase (TrxR) and MAPK pathways. The findings provide mechanistic insight into immunomodulation within the tumor microenvironment, suggesting potential for improved combination immunotherapy strategies.

• Heparin Sodium: Glycosaminoglycan Anticoagulant in Research

  2026-05-23

  Heparin sodium empowers precise anticoagulant workflows in thrombosis and advanced coagulation research, serving as a gold-standard glycosaminoglycan anticoagulant. Its validated performance in anti-factor Xa activity and aPTT assays, compatibility with innovative delivery methods, and consistent reproducibility make it indispensable for high-fidelity experimental models.

• CAY10499: Expanding Horizons in Lipid Metabolism and Immunom

  2026-05-22

  CAY10499, a potent inhibitor of human hormone sensitive lipase, is revolutionizing lipid metabolism and immunometabolic research. This article uniquely explores how CAY10499 enables precise dissection of lipid-driven immune modulation and highlights emerging insights from extracellular vesicle studies.

• 5-Azacytidine Workflow: Precision DNA Demethylation in Cance

  2026-05-22

  5-Azacytidine (5-AzaC) is a benchmark DNA demethylation agent, empowering researchers to dissect epigenetic silencing and reactivation in translational cancer models. This guide delivers stepwise protocols, advanced troubleshooting, and actionable insights, drawing from the latest breakthroughs in gastric cancer epigenetics.

16132 records 1/1076 page Next 12345 下5页 Last page